DolutegravirSodium , 2mMinDMSO , 1051375-19-9

CAS NO.：1051375-19-9

Empirical Formula: C20H20F2N3NaO5

Molecular Weight: 443.38

MDL number: MFCD28405599

EINECS: 812-620-6

PRODUCT Properties

• Melting point: >300oC
• storage temp.: Hygroscopic, -20°C Freezer, Under inert atmosphere
• solubility: DMSO (Slightly, Heated), Methanol (Slightly, Heated)
• form: Solid
• color: White to Green
• Stability: Hygroscopic
• InChIKey: FWLDGCYHMZPGGI-SBBUJZKLNA-N
• SMILES: O=C1N2[C@@H](CCO[C@@]2([H])CN2C=C(C(=O)NCC3C=CC(F)=CC=3F)C(=O)C(O)=C12)C.[NaH] |&1:3,7,r|

Description and Uses

Dolutegravir, also known as DTG or dolutegravir sodium, is an antiretroviral therapy drug used to treat HIV infection. It belongs to the Integrase Strand Transfer inhibitor (INSTi) class of drugs and was fast-tracked by the FDA in February 2012. GlaxoSmithKline developed and markets dolutegravir sodium (Tivicay), which received FDA approval in August 2013 as a novel integrase inhibitor for HIV treatment, including adults undergoing their first treatment as well as those who have been treated with other integrase transfer strand inhibiting agents.

Dolutegravir, a second-generation HIV-1 integrase strand transfer inhibitor, is commonly used along with other medications to manage HIV infection. Its potency in inhibiting HIV replication has been demonstrated in various cell types infected with a self-inactivating PHIV lentiviral vector, including peripheral blood mononuclear cells (PBMCs), MT-4 cells, and CIP4 cells.

Safety

• Symbol(GHS): GHS09
• Signal word: Warning
• Hazard statements: H400-H410
• Precautionary statements: P273-P391-P501-P273-P391-P501